Comparison of monoclonal antibody disposition predictions using different physiologically based pharmacokinetic modelling platforms
- PMID: 37952005
- DOI: 10.1007/s10928-023-09894-4
Comparison of monoclonal antibody disposition predictions using different physiologically based pharmacokinetic modelling platforms
Abstract
Physiologically based pharmacokinetic (PBPK) models can be used to leverage physiological and in vitro data to predict monoclonal antibody (mAb) concentrations in serum and tissues. However, it is currently not known how consistent predictions of mAb disposition are across PBPK modelling platforms. In this work PBPK simulations of IgG, adalimumab and infliximab were compared between three platforms (Simcyp, PK-Sim, and GastroPlus). Accuracy of predicted serum and tissue concentrations was assessed using observed data collected from the literature. Physiological and mAb related input parameters were also compared and sensitivity analyses were carried out to evaluate model behavior when input values were altered. Differences in serum kinetics of IgG between platforms were minimal for a dose of 1 mg/kg, but became more noticeable at higher dosages (> 100 mg/kg) and when reference (healthy) physiological input values were altered. Predicted serum concentrations of both adalimumab and infliximab were comparable across platforms, but were noticeably higher than observed values. Tissue concentrations differed remarkably between the platforms, both for total- and interstitial fluid (ISF) concentrations. The accuracy of total tissue concentrations was within a three-fold of observed values for all tissues, except for brain tissue concentrations, which were overpredicted. Predictions of tissue ISF concentrations were less accurate and were best captured by GastroPlus. Overall, these simulations show that the different PBPK platforms generally predict similar mAb serum concentrations, but variable tissue concentrations. Caution is therefore warranted when PBPK models are used to simulate effect site tissue concentrations of mAbs without data to verify the predictions.
Keywords: Adalimumab; Biodistribution; IgG; Infliximab; Monoclonal antibodies; Physiologically based pharmacokinetics.
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Conflict of interest statement
Declarations. Conflict of interest: The authors report no conflict of interest.
Similar articles
-
Interstitial IgG antibody pharmacokinetics assessed by combined in vivo- and physiologically-based pharmacokinetic modelling approaches.J Physiol. 2017 Dec 15;595(24):7311-7330. doi: 10.1113/JP274819. Epub 2017 Oct 29. J Physiol. 2017. PMID: 28960303 Free PMC article.
-
Simulation of monoclonal antibody pharmacokinetics in humans using a minimal physiologically based model.AAPS J. 2014 Sep;16(5):1097-109. doi: 10.1208/s12248-014-9640-5. Epub 2014 Jul 9. AAPS J. 2014. PMID: 25004823 Free PMC article.
-
Development and Application of a Physiologically-Based Pharmacokinetic Model to Predict the Pharmacokinetics of Therapeutic Proteins from Full-term Neonates to Adolescents.AAPS J. 2020 May 24;22(4):76. doi: 10.1208/s12248-020-00460-1. AAPS J. 2020. PMID: 32449129
-
Application of Modelling and Simulation Approaches to Predict Pharmacokinetics of Therapeutic Monoclonal Antibodies in Pediatric Population.Pharmaceutics. 2023 May 20;15(5):1552. doi: 10.3390/pharmaceutics15051552. Pharmaceutics. 2023. PMID: 37242793 Free PMC article. Review.
-
Opportunities and Challenges for PBPK Model of mAbs in Paediatrics and Pregnancy.AAPS J. 2022 Jun 1;24(4):72. doi: 10.1208/s12248-022-00722-0. AAPS J. 2022. PMID: 35650328 Review.
Cited by
-
Physiologically Based Pharmacokinetic Models for Infliximab, Ipilimumab, and Nivolumab Developed with GastroPlus to Predict Hepatic Concentrations.Pharmaceutics. 2025 Mar 14;17(3):372. doi: 10.3390/pharmaceutics17030372. Pharmaceutics. 2025. PMID: 40143035 Free PMC article.
-
A minimal physiologically based pharmacokinetic model to study the combined effect of antibody size, charge, and binding affinity to FcRn/antigen on antibody pharmacokinetics.J Pharmacokinet Pharmacodyn. 2024 Oct;51(5):477-492. doi: 10.1007/s10928-023-09899-z. Epub 2024 Feb 24. J Pharmacokinet Pharmacodyn. 2024. PMID: 38400996 Free PMC article.
References
-
- Tang Y, Li X, Cao Y (2021) Which factors matter the most? Revisiting and dissecting antibody therapeutic doses. Drug Discovery Today 26:1980–1990. https://doi.org/10.1016/j.drudis.2021.04.022 - DOI - PubMed - PMC
-
- Shah DK, Betts AM (2013) Antibody biodistribution coefficients. MAbs 5:297–305. https://doi.org/10.4161/mabs.23684 - DOI - PubMed - PMC
-
- Glassman PM, Abuqayyas L, Balthasar JP (2015) Assessments of antibody biodistribution. J Clin Pharmacol 55:S29–S38. https://doi.org/10.1002/jcph.365 - DOI - PubMed
-
- Garg A, Balthasar JP (2007) Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice. J Pharmacokinet Pharmacodyn 34:687–709. https://doi.org/10.1007/s10928-007-9065-1 - DOI - PubMed
-
- Lobo ED, Hansen RJ, Balthasar JP (2004) Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci 93:2645–2668. https://doi.org/10.1002/jps.20178 - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources